GSK Shifts Focus After Haleon Spinoff

July 26, 2022

With the spinoff of its consumer healthcare operations into the new company Haleon, GSK is turning its focus onto new technologies and currently untreated diseases. The company aims to catch back up with its competitors in the immuno-oncology field, a market space it previously wrote off. With the money freed up by the Haleon spinoff, analysts expect GSK to snap up small biotechs to help with these efforts. One potential target for this push is Cytodyn.

According to , “The company’s core areas include respiratory, HIV, immuno-inflammation and oncology, and the company is well known for its vaccines. Its main issue is that it lacks promising late stage immuno-inflammation and immuno-oncology drugs. CytoDyn remains a rare case of acquiring a company with a primary asset that can address all of the focus points of GSK’s new strategy post-spinoff. Not only that; it has a number of phase 2 indications and a BLA for its HIV entry inhibitor is expected to submit to the FDA for approval in 2023.”

To read more, click here.